About beta bionics inc - BBNX
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
BBNX At a Glance
Beta Bionics, Inc.
11 Hughes
Irvine, California 92618
| Phone | 1-949-427-7785 | Revenue | 65.12M | |
| Industry | Medical Specialties | Net Income | -54,756,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 442.926% | |
| Fiscal Year-end | 12 / 2025 | Employees | 291 | |
| View SEC Filings |
BBNX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
BBNX Efficiency
| Revenue/Employee | 223,793.814 |
| Income Per Employee | -188,164.948 |
| Receivables Turnover | 5.429 |
| Total Asset Turnover | 0.502 |
BBNX Liquidity
| Current Ratio | 6.285 |
| Quick Ratio | 5.656 |
| Cash Ratio | 4.898 |
BBNX Profitability
| Gross Margin | 55.107 |
| Operating Margin | -69.484 |
| Pretax Margin | -84.08 |
| Net Margin | -84.08 |
| Return on Assets | -42.171 |
| Return on Equity | -81.348 |
| Return on Total Capital | -65.759 |
| Return on Invested Capital | -76.397 |
BBNX Capital Structure
| Total Debt to Total Equity | 9.544 |
| Total Debt to Total Capital | 8.713 |
| Total Debt to Total Assets | 4.848 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 6.877 |